Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 31, 2014
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Wednesday, Feb. 11, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review fourth quarter and full year 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Feb. 11, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and ...
December 17, 2014
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a first quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share, an increase of 15% from the quarterly dividend rate paid in 2014. The dividend is to be paid on Tuesday, Mar. 3, 2015, to holders of record on Thursday, Jan. 22, 2015. “In 2014, we continued to demonstrate the strength of our business model and deliver our long-term value proposition, including returning capital to our shareholders through our quarterly dividends and recently announced share repurchase program,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “With the Board’s approval, I am pleased to announce we are increasing our dividend by 15% as we head into 2015 and continuing our commitment to effective and efficient use of our cash.” About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in ...
December 17, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the 33 rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 1:00 p.m. EST (10:00 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 ...
December 2, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal & Dental Health Summit on Thursday, Dec. 11, in Boston, Mass. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Clint Lewis, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. They are scheduled to present at 12:30 p.m. EST. The meeting is not scheduled to be webcast. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in ...
December 1, 2014
First broadly available, standardized Health Risk Assessment in veterinary medicine FLORHAM PARK, N.J., December 1, 2014 – Zoetis is pleased to announce that the American Animal Hospital Association (AAHA) has selected the company’s Pet Wellness Report® (PWR) as AAHA’s exclusive Preferred Business Provider for Health Risk Assessments in veterinary medicine. AAHA accredited hospitals are traditionally on the forefront of advancing new approaches to medical care for companion animals. The endorsement lends credibility to this innovative communication tool, which further enhances veterinary wellness efforts. The PWR is the first broadly available, standardized Health Risk Assessment for use in veterinary medicine. The report is designed to identify modifiable lifestyle risks, provide clues to early warning signs of disease, and facilitate client communication and education. PWR encourages greater pet owner involvement in the wellness care of their pet. “Preferred Business Provider status ...
November 24, 2014
Partners with Chinese Veterinary Medical Association and Kansas State University to facilitate knowledge sharing in veterinary education between United States and China QINGDAO, CHINA - November 24, 2014 - Zoetis, the Chinese Veterinary Medical Association (CVMA), and Kansas State University (KSU) signed a Memorandum of Understanding to work together and promote the Doctor of Veterinary Program (DVM) in China. This program aims to enhance veterinary services and veterinary training in the country by sharing the collective resources and providing other necessary support. The agreement was signed at the International Symposium on Veterinary Education held in Qingdao International Convention Center, jointly organized by CVMA, Kansas State University, and International Veterinary Collaboration for China (IVCC) and Zoetis. Maintaining the focus on the future of China’s veterinary education, the organizations committed to furthering China’s veterinary care by creating 50 DVMs in the coming ...
November 24, 2014
Trawicki joins Zoetis from GE Healthcare and brings more than 20 years of experience in healthcare manufacturing and operations to the role Zoetis Inc. (NYSE:ZTS) today announced the appointment of Roman Trawicki as President of its Global Manufacturing and Supply organization. With more than 20 years of broad, international experience in healthcare manufacturing and operations, Mr. Trawicki will oversee the company’s global manufacturing and supply network that produces more than 300 animal health product lines for the company. As the world leader in animal health, Zoetis utilizes a network of 27 internal manufacturing facilities and about 200 external suppliers to manufacture and deliver its products to veterinarians and livestock producers in more than 120 countries. Mr. Trawicki will join Zoetis from GE Healthcare, where he has been General Manager of Global Supply Chain for Medical Diagnostics focusing on diagnostics, injectable contrast media and nuclear medicines. In that role, ...
November 18, 2014
Highlights Attractive Investment Opportunity in Animal Health Industry Describes Zoetis' Competitive Advantage and Market Leadership Position Announces Full-Year 2015 Guidance of $1.61 to $1.68 for Adjusted Diluted Earnings Per Share 1 and Longer Term Financial Goals Through 2017 Zoetis Inc. (NYSE:ZTS), the world’s leading animal health company, today hosted its first-ever Investor Day, discussing with investors and analysts the company’s leadership position in the animal health industry and the strategy and initiatives underway that will drive growth and create value for shareholders. The company also provided full-year 2015 financial guidance and outlined its longer term financial goals through 2017. “Zoetis has become the world leader in the $23 billion market for animal health medicines and vaccines based on our unique combination of capabilities, our diverse portfolio of more than 300 product lines, our global presence in 120 countries and critical investments that we have made ...
November 18, 2014
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, today announced that its Board of Directors has authorized a $500 million share repurchase program as part of its capital allocation plans. The shares are expected to be repurchased at the discretion of management, depending on market conditions and business needs. The authorization allows for repurchases to be conducted through open market or privately negotiated transactions or otherwise. “A share repurchase program is an important tool for managing our allocation of capital, and it gives us additional flexibility to return capital to shareholders when it is not needed in the business,” said Paul Herendeen, Executive Vice President and Chief Financial Officer of Zoetis. “We remain focused on investing capital internally to help grow the business; completing complementary business development activities that can generate additional value; and returning capital to shareholders as part of our total value proposition.” ...
November 17, 2014
$255 million deal expands Zoetis companion animal product portfolio to bring veterinarians solutions for pain, diabetes and oncology Transaction furthers Zoetis’ bolt-on acquisition strategy aimed at expanding complementary animal health businesses to create additional value for shareholders Zoetis Inc. (NYSE:ZTS) today announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million. Abbott Animal Health is a companion animal health business focused on the veterinary surgical suite. This acquisition will strengthen Zoetis’ companion animal product portfolio and expand its diagnostics business as more pets are being treated for pain and serious illnesses, such as cancer and diabetes. Headquartered in Abbott Park, Illinois, Abbott Animal Health has a presence in nearly 20 countries and holds a market-leading position with products in anesthesia, fluid therapy, pain, oncology and diabetes monitoring. “The addition of Abbott Animal Health assets is ...
November 14, 2014
Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has adopted a one-year shareholder rights plan (the “Plan”) and declared a dividend distribution of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock. The Plan will automatically expire on November 16, 2015, unless the Rights are earlier redeemed, exchanged or terminated. The Plan is intended to protect shareholders and the Company from any attempt to take control of the Company that the Board of Directors determines is not in the best interest of shareholders and does not reflect the Company’s unique industry position and long term value. It is also designed to provide the Board sufficient time to make fully informed decisions in response to any open market or other accumulation of shares. The Plan is not intended to prevent an offer to acquire the Company or any other business combination the Board may approve and, as such, may be amended, redeemed or terminated ...
November 13, 2014
Zoetis to Lead $3 Million Project Funded by Agri-Tech Catalyst Award from Innovate UK, the UK’s Innovation Agency LONDON, UK – Nov. 13, 2014 - A consortium of academic and animal health industry partners in the UK, led by Zoetis Inc., is embarking on a pioneering 42-month project that will develop visual imaging methods and digital technologies to help producers improve the health and wellness of pig herds and enhance production efficiency.  The $3 million (USD) project, announced today, is funded by an Agri-Tech Catalyst Award from Innovate UK, the UK’s innovation agency.  The partners will develop these advanced technologies to analyse pig behaviour and performance, looking for early warning signs of disease or stress and pave the way to treatment and care sooner than has previously been possible. “This work has the potential to hasten the advent of precision farming in pork production and is a strong example of Zoetis’ commitment to innovative services and technologies for our ...
November 5, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, Dec. 2, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Dr. Catherine Knupp, Executive Vice President and President, Research and Development, will represent the company and respond to questions from analysts. They are scheduled to present at 8:30 a.m. EST. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. ...
November 4, 2014
Third Quarter 2014 Revenue of $1.2 Billion Increased 10%, Compared to Third Quarter 2013 Third Quarter 2014 Reported Net Income of $166 Million, or Diluted EPS of $0.33, Increased 27%, Compared to Third Quarter 2013 Third Quarter 2014 Adjusted Net Income of $207 Million, or Adjusted Diluted EPS 1 of $0.41, Increased 20% and 21%, Respectively, Compared to Third Quarter 2013 Company Reaffirms Full-Year 2014 Adjusted Diluted EPS 1 Guidance of $1.50 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2014. The company reported revenue of $1.2 billion for the third quarter of 2014, an increase of 10% from the third quarter of 2013. Revenue reflected an operational2 increase of 10%, with foreign currency having no material impact on revenue growth this quarter. Net income for the third quarter of 2014 was $166 million, or $0.33 per diluted share, an increase of 27%, compared to the third quarter of 2013. Adjusted net income 1 for the third quarter of ...
October 27, 2014
Collaboration will advance surveillance and research for the benefits of human and animal health PARIS, FRANCE - October 27, 2014 – A new European research centre, comprising a collaborative network of veterinarians, scientists and technical specialists with a coordinating hub in Edinburgh, Scotland, aims to identify emerging diseases in livestock and companion animals, and enhance the ability to control them. This centre of excellence is a collaboration between the Easter Bush Research Consortium (EBRC) and global animal health company Zoetis.  This collaboration forms a part of Zoetis’ European and global efforts to combat Emerging Infectious Diseases in animals and will work with veterinarians and other researchers throughout Europe and beyond. It will draw on the unique expertise of each consortium member to help rapidly identify and combat emerging diseases in animals and help protect the livelihoods of those who raise and care for them. Capacity to genetically sequence and ...
October 2, 2014
The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a fourth quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on Tuesday, Dec. 2, 2014, to holders of record on Wednesday, Nov. 5, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 27 manufacturing facilities in 10 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 ...
September 30, 2014
Zoetis Inc. (NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, November 4, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review third quarter 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on November 4, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported ...
September 16, 2014
Working Mother magazine recognizes Zoetis for its commitment to providing colleagues with opportunities for growth, advancement and work-life balance Zoetis Inc. (NYSE:ZTS) today announced that it has been named among the top 10 on Working Mother magazine’s "100 Best Companies for Working Mothers" list. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as child care, flexibility, advancement and paid family leave. “Zoetis is honored to be named one of Working Mother magazine’s top ten companies in our first year as an independent public company,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer at Zoetis. “We know our colleagues are critical to our success and vital to our customers. In establishing Zoetis, we have built a culture that truly supports our people and recognizes their importance. This means we are committed to the success of working mothers at Zoetis and ...
September 3, 2014
New vaccine and expertise will help pig farmers and veterinarians fight deadly disease Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs. The two-dose inactivated vaccine, licensed for use in healthy pregnant female pigs (sows and gilts), is designed to help them develop antibodies which can be transmitted to their newborn piglets. Zoetis anticipates the vaccine will be available to veterinarians and pig farmers in September. “We at Zoetis are proud to provide our customers with a vaccine to help battle this devastating disease,” said Catherine Knupp, executive vice president and president, Zoetis Research and Development. “Rapidly emerging infectious diseases such as PEDv not only threaten animal health but also the livelihoods of farmers. Bringing this vaccine to market quickly – in a little more than a year since the disease was identified ...
August 20, 2014
Combination vaccine gives swine industry effective, convenient option FLORHAM PARK, N.J., Aug. 20, 2014 — Fostera™ PCV MH — the porcine circovirus (PCV) and Mycoplasma hyopneumoniae (M. hyo) combination vaccine that was built from the ground up by Zoetis — now has the longest demonstrated duration of immunity (DOI) to help protect pigs from porcine circovirus-associated disease (PCVAD) caused by PCV Type 2 (PCV2). The U.S. Department of Agriculture has granted the combination vaccine the extended label claim of at least 23 weeks of protection against PCV2, which is three weeks longer than any other PCV2 vaccine on the market. “PCVAD continues to be one of the most economically harmful swine diseases. Affected pigs suffer from progressive weight loss, increased mortality and other clinical impacts, which takes a toll on producers’ productivity and profitability,” said Darrell Neuberger, DVM, Pork Technical Services, Zoetis. “Now, with a vaccine that offers at least 23 weeks of ...
August 20, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 18, in London, UK. Juan Ramón Alaix, Chief Executive Officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 6:25 a.m. EDT (11:25 a.m. BST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately ...
August 14, 2014
Herendeen brings 16 years of experience as CFO and substantial background in health care Zoetis Inc. (NYSE:ZTS) today announced the appointment of Paul Herendeen as its new Executive Vice President and Chief Financial Officer (EVP & CFO), completing a leadership transition that began in April. Herendeen has spent the last 16 years in CFO roles at health care companies Warner Chilcott and MedPointe, building on a successful career in finance, banking and private equity partnerships. In his role at Zoetis, Herendeen will oversee the company’s Finance and Information Technology (IT) organizations and be part of the Zoetis Executive Team, reporting to CEO Juan Ramón Alaix. He will have responsibility for the financial management, planning and operations for the company’s $4.6 billion enterprise. He will also leverage his past experiences with IT to oversee the implementation of an Enterprise Resource Planning (ERP) system based on SAP, a significant undertaking to complete the company’s ...
August 13, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 2:05 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at ...
August 5, 2014
Zoetis Inc. (NYSE:ZTS) today announced it will hold its inaugural Investor Day for financial analysts on Tuesday, Nov. 18, at the New York Stock Exchange. The event, hosted by Chief Executive Officer Juan Ramón Alaix and other members of the Zoetis executive team, will be used to provide investors with information on the company’s strategy, capabilities and value proposition, as well as the overall animal health industry. Investors and the public may access a live audio webcast of the event and presentation materials by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available today. A replay of the webcast will be archived and made available on Nov. 18, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures ...
August 5, 2014
Second Quarter 2014 Revenue of $1.2 Billion Increased 4%, Compared to Second Quarter 2013 Second Quarter 2014 Reported Net Income of $136 Million, or Diluted EPS of $0.27, Increased 6% and 4%, respectively, Compared to Second Quarter 2013 Second Quarter 2014 Adjusted Net Income of $189 Million, or Adjusted Diluted EPS 1 of $0.38, Increased 6% Compared to Second Quarter 2013 Company Narrows Full-Year 2014 Adjusted Diluted EPS 1 Guidance to $1.50 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2014. The company reported revenue of $1.2 billion for the second quarter of 2014, an increase of 4% from the second quarter of 2013. Revenue reflected an operational 2 increase of 6%, with foreign currency having a negative impact of 2 percentage points. Net income for the second quarter of 2014 was $136 million, or $0.27 per diluted share, an increase of 6% and 4%, respectively, compared to the second quarter of 2013. Adjusted net income1 for the ...
July 31, 2014
The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a third quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on Tuesday, Sept. 2, 2014, to holders of record on Wednesday, Aug. 20, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 ...
July 28, 2014
Makes Rapid and Early Detection of Common Illness in Dairy Cows Possible Zoetis Inc. today announced the introduction of on-farm cattle health screening tests for the dairy industry in China. These tests will enable China’s dairy farmers and veterinarians to rapidly screen cattle on the farm for sub-clinical mastitis and ketosis, two of the leading causes of lost production and poor milk quality in China.  Test results will be available within five minutes, providing a quick, convenient tool to rapidly detect early signs of sub-clinical disease and help veterinarians and farmers better monitor and protect the health of dairy cows. “In China, the incidence of sub-clinical mastitis and ketosis is about 10 to 30 percent with as many as 1.5 million milking cows at risk of these illnesses,” said Qing Wang, general manager, Zoetis in China. “Zoetis is committed to helping dairy farmers and veterinarians improve herd health and operational profit by providing a holistic solution that ...
June 30, 2014
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, August 5, 2014. Chief Executive Officer Juan Ramón Alaix and Senior Vice President of Finance Operations and Acting Chief Financial Officer Glenn David will review second quarter 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on August 5, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic ...
June 3, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Goldman Sachs 35 th Annual Global Healthcare Conference on Tuesday, June 10, in Rancho Palos Verdes, Calif. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 4:20 p.m. EDT (1:20 p.m. PDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With ...
May 23, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 34 th Annual Growth Stock Conference on Thursday, June 12, in Chicago, Ill. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:40 a.m. EDT (8:40 a.m. CDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 ...
May 13, 2014
Zoetis Inc. (NYSE:ZTS) marked another milestone in the company’s launch as an independent public company today, conducting its first-ever Annual Meeting of Shareholders. The company, which became fully independent in June 2013 after completing its separation from Pfizer, hosted the event this morning at the Hilton Short Hills Hotel, in Short Hills, New Jersey. Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. He was joined by Zoetis Chief Executive Officer Juan Ramón Alaix who discussed the company’s first year as an independent company, the core strengths of its business model, and its long-term value proposition for shareholders. A full replay of the meeting is available at http://investor.zoetis.com/events-presentations , along with a copy of Mr. Alaix’s prepared remarks and presentation. Preliminary results from the Annual Meeting of Shareholders indicate the following results of shareholder voting: Gregory Norden, Louise ...
May 9, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the BMO Capital Markets 2014 Farm to Market Conference on Thursday, May 22, in New York, NY. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 1:30 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide ...
May 6, 2014
First Quarter 2014 Revenue of $1.1 Billion Increased 1%, Compared to First Quarter 2013 First Quarter 2014 Reported Net Income of $155 Million, or Diluted EPS of $0.31, Increased 11%, Compared to First Quarter 2013 First Quarter 2014 Adjusted Net Income of $191 Million, or Adjusted Diluted EPS 1 of $0.38, Increased 7% and 6%, Respectively, Compared to First Quarter 2013 Company Reaffirms Full-Year 2014 Adjusted Diluted EPS 1 Guidance of $1.48 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational 2 increase of 4%, with foreign currency having a negative impact of 3 percentage points. Net income for the first quarter of 2014 was $155 million, or $0.31 per diluted share, an increase of 11%, compared to the first quarter of 2013. Adjusted net income1 for the first quarter of 2014 was $191 ...
April 22, 2014
Company Announces Current CFO Rick Passov to Leave at End of April Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, senior vice president of Finance Operations, has been named acting Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company’s financial management and global operations, effective immediately. David will succeed Executive Vice President and Chief Financial Officer Richard (Rick) Passov, who will be leaving the company at the end of April. “Glenn is a tenured, well-respected leader in our organization,” said Chief Executive Officer Juan Ramón Alaix. “His deep financial experience and knowledge of the animal health business has been serving Zoetis well, and I have every confidence in his ability to steward our financial operations at this time.” With David in place as acting CFO, reporting to Alaix, the company indicated it will commence a search process among internal and external candidates for the chief financial officer ...
April 8, 2014
Zoetis joined a new initiative working to advance the standards of small animal veterinary care across Africa. The African Small Companion Animal Network (AFSCAN) aims to facilitate the creation of a sustainable network of companion animal veterinarians, associations and specialist groups in sub-Saharan Africa. This network will facilitate the formation of new Small Animal Veterinary Associations (SAVAs) across the continent. Read the full press release here . ...
March 31, 2014
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, May 6, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first quarter 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on May 6, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of ...
March 26, 2014
The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a second quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on June 2, 2014 to holders of record on April 28, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more ...
March 13, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 27, at the Jefferies Conference Center in New York, NY. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. Investors and other interested parties will be able to access the presentation materials by visiting http://investor.zoetis.com/events-presentations after the presentation is delivered. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the ...
March 4, 2014
Zoetis Inc. (NYSE:ZTS) today announced the appointment of Dr. Willie M. Reed, Dean of the College of Veterinary Medicine at Purdue University, to its Board of Directors. Dr. Reed will serve on the Corporate Governance Committee of the Board. Dr. Reed has more than 30 years of experience in animal health and veterinary medicine, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of the American College of Veterinary Pathologists and Charter Diplomate of the American College of Poultry Veterinarians. Dr. Reed served as president of the Association of American Veterinary Medical Colleges (AAVMC), president of the American Association of Veterinary Laboratory Diagnosticians (AAVLD), president of the American Association of Avian Pathologists (AAAP) and chair of the American Veterinary Medical Association Council on Research. He currently serves on the American Veterinary Medical Association’s (AVMA) Member Services Committee. As a recognized ...
February 26, 2014
A Total of $100,000 Available to Fund Feline Pain, Osteoarthritis, Joint Health and Kidney Disease Research FLORHAM PARK, N.J. - February 26, 2014 - The Winn Feline Foundation, in a unique funding opportunity sponsored by Zoetis Inc., announced today a call for proposals to address the assessment of pain, osteoarthritis, joint health and kidney disease in cats. A total of $100,000 is available to fund proposals of sufficient scientific merit, relevance and potential to impact feline health. Consideration will be given to proposals investigating novel biomarkers for assessing acute or chronic adaptive pain and maladaptive (i.e., neuropathic or functional) pain in cats. Biomarkers for assessing osteoarthritis progression are also of interest. Scientifically sound projects that investigate the cause and progression of osteoarthritis in cats will also be considered, regardless of biomarker assessment.  Additionally, because methods for early detection and progression of feline chronic ...
February 20, 2014
Zoetis Inc. (NYSE:ZTS) today announced that the company’s 2014 Annual Meeting of Shareholders will be held on Tuesday, May 13, 2014 at 10:00 a.m. ET at the Hilton Short Hills Hotel, 41 John F. Kennedy Parkway, Short Hills, NJ 07078. Additional information regarding deadlines for shareholders’ proposals will be filed with the Securities and Exchange Commission by Zoetis on a Current Report on Form 8-K. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing ...
February 11, 2014
Fourth Quarter 2013 Revenue of $1.25 Billion Increased 7% Compared to Fourth Quarter 2012 Fourth Quarter 2013 Reported Net Income of $105 Million, or $0.21 per Diluted Share Fourth Quarter 2013 Adjusted Net Income of $180 Million, or Adjusted Diluted EPS 1 of $0.36 For Full Year 2013, Revenue of $4.56 Billion Increased 5%; Adjusted Net Income of $709 Million, or Adjusted Diluted EPS 1 of $1.42, Increased 32% and 31%, respectively Company Sets Full-Year 2014 Guidance for Revenue of $4.65 - $4.75 Billion and Adjusted Diluted EPS 1 of $1.48 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational 2 increase of 9%, with foreign currency having a negative impact of 2 percentage points. Net income for the fourth quarter of 2013 was $105 million, or $0.21 per diluted share. ...
February 10, 2014
Collaboration focuses on developing and testing vaccine candidate for swine FLORHAM PARK, N.J., Feb. 10, 2014 — Zoetis Inc. today announced a research partnership with Iowa State University (ISU) to identify and test a vaccine candidate to help control porcine epidemic diarrhea virus (PEDv) in the United States. “Establishing this partnership further affirms our commitment to fighting this devastating virus,” said Gloria Basse, vice president, U.S. Pork Business Unit, Zoetis. “We look forward to working with the top researchers at Iowa State University to share knowledge and expertise as we make every effort, together, to help veterinarians and producers fight PEDv.” New cases of PEDv continue to mount. Since the beginning of December, more than 100 new cases have been reported each week.1 PEDv now has spread to swine farms in 23 states since April 2013, with documented farm cases in the thousands. Losses from PEDv are significant and have been measured on some farms at 100% mortality ...
January 29, 2014
First Janus Kinase Inhibitor Approved for Veterinary Use in Europe PARIS, FRANCE, January 29, 2014 – Zoetis Inc. announced today the launch of Apoquel® (oclacitinib maleate), a novel therapy indicated for the treatment of pruritus (itching) associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Veterinarians across Europe now have a first-in-class treatment choice that targets the itch of allergic skin conditions in dogs. Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. It provides rapid and sustained relief of pruritus and improves skin lesions without the side-effects associated with commonly-used therapies, such as glucocorticoids. Canine pruritus is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition for which Apoquel would be indicated. Pascal Prélaud, a dermatology ...
January 20, 2014
First Veterinary Janus kinase Inhibitor Targets the Itch of Allergic Skin Conditions at Its Source FLORHAM PARK, N.J. – Jan. 20, 2014 – Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition where APOQUEL would be indicated. “When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. After gaining five years of experience with APOQUEL through my involvement in clinical trials, I’ve ...
January 14, 2014
IMPROVEST ® life cycle assessment and Environmental Product Declaration represents first to be awarded to animal health company FLORHAM PARK, N.J. - Zoetis recently unveiled new research that will help pork producers and meat packers produce wholesome pork with less environmental impact. The research is based on a life cycle assessment (LCA) conducted in the United States for IMPROVEST® (gonadotropin releasing factor analog – diphtheria toxoid conjugate), an FDA-approved veterinary prescription product that successfully reduces unpleasant odors that can occur when cooking pork from some male pigs. The LCA found that even modest adoption rates (33%) of IMPROVEST on U.S. pig farms could generate significant environmental benefits. 1 This outcome reinforced findings of a Lifecycle Assessment conducted in countries outside the U.S. which supported the Environmental Product Declaration (EPD ® ) granted to IMPROVEST issued by the International Environmental Consortium in 2012.  The U.S. ...